Loomis Sayles & Co. L P Sells 49,096 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Loomis Sayles & Co. L P lowered its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,467,027 shares of the specialty pharmaceutical company's stock after selling 49,096 shares during the period. Loomis Sayles & Co. L P owned about 2.66% of Supernus Pharmaceuticals worth $53,048,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SUPN. JPMorgan Chase & Co. lifted its stake in Supernus Pharmaceuticals by 17.5% in the fourth quarter. JPMorgan Chase & Co. now owns 297,810 shares of the specialty pharmaceutical company's stock worth $10,769,000 after purchasing an additional 44,414 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $52,000. Prudential Financial Inc. boosted its holdings in Supernus Pharmaceuticals by 14.3% during the 4th quarter. Prudential Financial Inc. now owns 66,733 shares of the specialty pharmaceutical company's stock valued at $2,374,000 after acquiring an additional 8,352 shares during the period. Vanguard Group Inc. grew its position in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock worth $222,411,000 after acquiring an additional 22,852 shares during the last quarter. Finally, Bridge City Capital LLC grew its position in Supernus Pharmaceuticals by 0.8% during the 4th quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company's stock worth $3,435,000 after acquiring an additional 761 shares during the last quarter.

Remove Ads

Supernus Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ SUPN traded down $0.35 on Tuesday, reaching $32.41. 111,347 shares of the company's stock traded hands, compared to its average volume of 476,467. The business's 50 day simple moving average is $35.05 and its two-hundred day simple moving average is $35.06. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The company has a market cap of $1.81 billion, a price-to-earnings ratio of 30.22 and a beta of 0.83.

Analyst Ratings Changes

A number of research firms have recently weighed in on SUPN. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com downgraded Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, March 24th.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.